💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for EXACT Sciences Corporation (EXAS)
« Back to company indexEXAS Chatter Timeline
Stock Ticker for EXAS
Most Active Tweeters for EXAS
| User | Tweets |
|---|---|
| @andrewross11 | 13 |
| @SweepCastApp | 9 |
| @MrCosmoKraymer | 8 |
| @Gambiste1 | 7 |
| @Tickeron | 7 |
Recent Tweets for EXAS
 |
@TradeWithAlerts A nice print for $EXAS at 5:31pm -- SIDE: NearBid Click https://t.co/Wz0a1KdTR9 for more. Runners ?:… https://t.co/wyhIF4xqC0 December 3rd 2021, 10:12pm |
 |
@ShortAlgoTrades $EXAS Waiting for Buy signal, https://t.co/krvdST13aO December 3rd 2021, 7:12pm |
 |
@VatqLu $EXAS Waiting for Buy signal, https://t.co/p1clm8AHvW December 3rd 2021, 7:12pm |
|
@ShortAlgoTrades $EXAS Awaiting Buy Signal. Stock Trading Ideas by https://t.co/jpmUt7BvVp https://t.co/pIMGIa7w7m December 3rd 2021, 6:12pm |
 |
@andrewross11 $exas add 500 to long (2000) @ 75.32! December 3rd 2021, 4:12pm |
|
@andrewross11 $exas long 1500 @ 77.88-.89! December 3rd 2021, 2:12pm |
 |
@VapzerSignals Scanner #stocks @ 12/03/2021 5:01 AM PST TF: 1 hr ? Buy: 1/104 $EXAS @ 137.94 ? Sell: 0/104 #StockTrades #Money December 3rd 2021, 1:12pm |
 |
@mediasentiment $EXAS new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 238 December 3rd 2021, 12:12pm |
|
@mediasentiment $EXAS new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 237 December 3rd 2021, 12:12pm |
 |
@Gambiste1 RT @MrCosmoKraymer: $EXAS price target of around $97 for 2022. Thinking this is a worst case scenario. Expecting revenues to be higher th… December 3rd 2021, 5:12am |
|
@Gambiste1 RT @MrCosmoKraymer: No official revenue guidance for '22 by $EXAS has been provided. $EXAS has reached a bottoming and oversold area. D… December 3rd 2021, 5:12am |
 |
@MrCosmoKraymer $EXAS /6 https://t.co/k88TscmnC3 December 3rd 2021, 4:12am |
|
@MrCosmoKraymer $EXAS ", which is also working on an updated version of Cologuard and a colon cancer blood test, is focusing much o… https://t.co/OLhAUWGEp3 December 3rd 2021, 4:12am |
|
@MrCosmoKraymer $EXAS price target of around $97 for 2022. Thinking this is a worst case scenario. Expecting revenues to be highe… https://t.co/brsaj1FstR December 3rd 2021, 3:12am |
|
@MrCosmoKraymer No official revenue guidance for '22 by $EXAS has been provided. $EXAS has reached a bottoming and oversold area… https://t.co/SRCa6VLFg8 December 3rd 2021, 3:12am |
|
@MrCosmoKraymer $EXAS - NOT investment advice! Leader in oncology screening => @Cologuard and liquid biopsies screenings in the pi… https://t.co/Bz5H620y5B December 3rd 2021, 3:12am |
 |
@SweepCastApp SweepCast alerted: $EXAS with Unusual Options Activity Alerted on $95 CALL Expiring: 01-21-2022 worth 26K? |? Check… https://t.co/nSlZQAQzTa December 3rd 2021, 12:12am |
 |
@aboutheoptions $EXAS Exact Sciences (EXAS) highlights publication of RxPONDER trial results in The New England Journal of Medicine December 2nd 2021, 11:12pm |
 |
@Tickeron $EXAS enters a Downtrend because Momentum Indicator dropped below the 0 level on November 10, 2021. View odds for t… https://t.co/6tR0lpu2bR December 2nd 2021, 11:12pm |
|
@Tickeron Do you agree with the A.I. prediction? $EXAS RSI Indicator left the oversold zone. #ExactSciences… https://t.co/O5DxLZiA27 December 2nd 2021, 8:12pm |
 |
@TortozaLeandro $EXAS Awaiting for Buy signal on EXAS with https://t.co/BVorhZSlcz https://t.co/aCewR8ShpS December 2nd 2021, 8:12pm |
|
@andrewross11 $exas sold long (1000) @ 80.20.21! December 2nd 2021, 7:12pm |
|
@andrewross11 $exas long 1000 @ 79.27-.29! December 2nd 2021, 6:12pm |
 |
@QuantchaIdeas 52-Week Low Alert: Trading today’s movement in EXACT SCIENCES $EXAS https://t.co/6voCaZqmKJ December 2nd 2021, 5:12pm |
|
@andrewross11 $exas sold long (1000) @ 80.38-.39! December 2nd 2021, 4:12pm |
|
@andrewross11 $exas long 1000 @ 79.00! December 2nd 2021, 3:12pm |
|
@andrewross11 $exas sold long (1000) @ 83.32-.33! December 2nd 2021, 2:12pm |
 |
@MarcJacksonLA $EXAS Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positiv… https://t.co/F6NpouPrii December 2nd 2021, 2:12pm |
 |
@NewsoftheMarket $EXAS Inst Own 91.30% Inst Trans 1.80% Gross Margin 75.00% Perf YTD -39.41% Exact Sciences let a co-promotion… https://t.co/xV2Lw6pYrh December 2nd 2021, 1:12pm |
|
@Tickeron $EXAS in -0.93% Downtrend, declining for three consecutive days on November 22, 2021. View odds for this and other… https://t.co/NVu87tqk40 December 2nd 2021, 4:12am |
 |
@Briefingcom $EXAS: Exact Sciences highlights publication of RxPONDER trial results in The New England Journal of Medicine https://t.co/NT9t6YgbAf December 2nd 2021, 12:12am |
|
@MarcJacksonLA $EXAS $PFE Exact Sciences Breaks Up With Pfizer. Is It Time To Buy? https://t.co/XTdR0a8IQd December 1st 2021, 10:12pm |
 |
@vtmtrading Exact Sciences announces RxPONDER trial data on Oncotype DX published in NEJM $EXAS December 1st 2021, 10:12pm |
 |
@phasefivebot $EXAS Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positiv… https://t.co/38M26lIpAy December 1st 2021, 10:12pm |
 |
@StockNewsBot2 $EXAS Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positiv… https://t.co/8Hwj7RtfsG December 1st 2021, 10:12pm |
 |
@stock_titan $EXAS Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positiv… https://t.co/4nhcTs5Moe December 1st 2021, 10:12pm |
|
@andrewross11 $exas long 1000 @ 80.76! December 1st 2021, 8:12pm |
 |
@tagthatstock $exas getting into that chicken leg area where nothing but chicken shit happens. December 1st 2021, 8:12pm |
|
@tagthatstock $exas is a 'cling on turd' their window to issue shares at a high price is disappearing. https://t.co/hEluP6WuqC December 1st 2021, 7:12pm |
|
@tagthatstock plenty of room for $EXAS to drop,, market has to correct the valuations at some point. https://t.co/ArcEB2edOx November 30th 2021, 11:11pm |
|
@SweepCastApp SweepCast alerted: $EXAS with Unusual Options Activity Alerted on $92.5 CALL Expiring: 01-21-2022 worth 28K? |? Che… https://t.co/2t8QPjRsdw November 30th 2021, 10:11pm |
|
@Tickeron $EXAS in Uptrend: RSI indicator exits oversold zone. View odds for this and other indicators:… https://t.co/Nmsj9Tg3N6 November 30th 2021, 9:11pm |
 |
@sleekoptions $EXAS stock was down -1.22%. Turned Positive 2.89% | (Red to green move) #RedToGreen See other red to green mov… https://t.co/OCBD8CP2mZ November 30th 2021, 6:11pm |
|
@tagthatstock probably the last warning $exas $85 bulls get to get OUT those who wrote puts need to get them back asap https://t.co/Lbbj5h5P1t November 30th 2021, 6:11pm |
 |
@LlcBillionaire EXACT Sciences Corporation (NASDAQ: $EXAS), Pfizer, Inc. (NYSE: $PFE) – Pfizer Will Not Co-Promote Exact Sciences C… https://t.co/zHlhDacTyI November 30th 2021, 4:11pm |
 |
@1anOnlyMary EXACT Sciences Corporation (NASDAQ: $EXAS), Pfizer, Inc. (NYSE: $PFE) – Pfizer Will Not Co-Promote Exact Sciences C… https://t.co/7PyQhRVhpH November 30th 2021, 4:11pm |
|
@Gambiste1 RT @MorrisBubba: @Crisprtalk I’m buying $PENN one of the lowest PE stocks you will find in this market. Tell me what you like about $EXAS November 30th 2021, 3:11pm |
 |
@MorrisBubba @Crisprtalk I’m buying $PENN one of the lowest PE stocks you will find in this market. Tell me what you like about $EXAS November 30th 2021, 2:11pm |
 |
@Crisprtalk I'm finding $penn and $exas very interesting here. November 30th 2021, 2:11pm |
 |
@john_bresnahan $EXAS & $PFE Am I just squinting too hard or does the end of this collaboration open the door to Pfizer doing some… https://t.co/UCNQbEKRAj November 30th 2021, 12:11pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?